Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH calibrated anti-Xa assays at VTE prophylactic dos...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaitlin Blotske PharmD, Toral Patel PharmD, BCPS, Toby Trujillo PharmD, FCCP, FAHA, BCPS, Matthew Marlar MLS (ASCP), Stuart Lind MD, Henry Kramer MD, Kathryn Hassell MD, Tyree H. Kiser PharmD, FCCM, FCCP, BCCCP, BCPS
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296251319961
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/10760296251319961

Similar Items